Our study not only for the first time systematically discussed the role and possible molecular mechanisms of Gal-3 in ICC, also provided experimental basis for further exploring the possibility of Gal-3 as a potential therapeutic target for treating ICC patients or those compromised with COVID-19. This evidence concerns the gene LGALS3 and intrahepatic cholangiocarcinoma.